Inclusion Criteria:

- Untreated multiple myeloma requiring treatment

- Total cumulative dose of prior doxorubicin can not exceed 240 mg/m2

- Must have measurable disease

- Left Ventricular Ejection Fraction (LVEF) >= 50 % determined by Multiple Gated
Acquisition Scan (MUGA)

- Karnofsky performance status of >= 60%

- Adequate bone marrow, liver and renal function

- Disease-free from prior malignancies >= 5 years with the exception of basal cell or
squamous cell carcinoma of the skin or carcinoma in situ of the cervix

- Female participants (if of child bearing potential and sexually active) and male
participants (if sexually active with a partner of child-bearing potential) must use
medically acceptable methods of birth control.

Exclusion Criteria:

- Life expectancy of >= 3 months

- Pregnant or breast feeding

- History of cardiac disease, with New York Heart Association Class II or greater, with
congestive heart failure

- or unstable angina, uncontrolled hypertension or cardiac arrythmias or myocardial
infarction within the last 6 months

- Uncontrolled diabetes mellitus or systemic infection

- Nonsecretory myeloma, Monoclonal Gammopathy of Unknown Significance (MGUS) or
smoldering myeloma

- Confusion, disorientation, or history of psychiatric illness which may impair
patient's ability to give informed consent

- Prior chemotherapy to treat Multiple Myeloma

- Prior radiotherapy to an area greater than 1/3 of the skeleton

- Prior local radiotherapy within 1 week of treatment

- Any investigational agent within 30 days of the first dose of treatment

- Prior single agent dexamethasone (or another corticosteroid) to treat Multiple
Myeloma.